JP2023539847A - 肺線維症を治療するためのフェンレチニド又はその類似体の使用 - Google Patents

肺線維症を治療するためのフェンレチニド又はその類似体の使用 Download PDF

Info

Publication number
JP2023539847A
JP2023539847A JP2023512721A JP2023512721A JP2023539847A JP 2023539847 A JP2023539847 A JP 2023539847A JP 2023512721 A JP2023512721 A JP 2023512721A JP 2023512721 A JP2023512721 A JP 2023512721A JP 2023539847 A JP2023539847 A JP 2023539847A
Authority
JP
Japan
Prior art keywords
fenretinide
analog
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539847A5 (https=
Inventor
ラドゥ ピスラリウ，
イレネイ キアニカ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laurent Pharmaceuticals Inc
Original Assignee
Laurent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurent Pharmaceuticals Inc filed Critical Laurent Pharmaceuticals Inc
Publication of JP2023539847A publication Critical patent/JP2023539847A/ja
Publication of JP2023539847A5 publication Critical patent/JP2023539847A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023512721A 2020-08-25 2021-08-19 肺線維症を治療するためのフェンレチニド又はその類似体の使用 Pending JP2023539847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069881P 2020-08-25 2020-08-25
US63/069,881 2020-08-25
PCT/CA2021/051148 WO2022040782A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Publications (2)

Publication Number Publication Date
JP2023539847A true JP2023539847A (ja) 2023-09-20
JP2023539847A5 JP2023539847A5 (https=) 2024-07-01

Family

ID=80352354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512721A Pending JP2023539847A (ja) 2020-08-25 2021-08-19 肺線維症を治療するためのフェンレチニド又はその類似体の使用

Country Status (10)

Country Link
US (1) US20230310352A1 (https=)
EP (1) EP4203931A4 (https=)
JP (1) JP2023539847A (https=)
KR (1) KR20230079054A (https=)
CN (1) CN116437904A (https=)
AU (1) AU2021329999A1 (https=)
BR (1) BR112023003481A2 (https=)
CA (1) CA3128648A1 (https=)
MX (1) MX2023002347A (https=)
WO (1) WO2022040782A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170957A2 (en) * 2011-06-08 2012-12-13 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of hsp47 expression
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
WO2012170957A2 (en) * 2011-06-08 2012-12-13 Nitto Denko Corporation Retinoid-liposomes for enhancing modulation of hsp47 expression

Also Published As

Publication number Publication date
BR112023003481A2 (pt) 2023-05-09
WO2022040782A1 (en) 2022-03-03
EP4203931A4 (en) 2024-11-13
KR20230079054A (ko) 2023-06-05
EP4203931A1 (en) 2023-07-05
MX2023002347A (es) 2023-04-20
CN116437904A (zh) 2023-07-14
US20230310352A1 (en) 2023-10-05
AU2021329999A1 (en) 2023-03-23
CA3128648A1 (en) 2022-02-25

Similar Documents

Publication Publication Date Title
US20200268768A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US20200000772A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
ES2596554T3 (es) Comprimidos de acetato de ulipristal
US10398713B2 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
JP2014520842A (ja) モンテルカストおよびリボセチリジン配合のカプセル製剤
US20130005763A1 (en) Sustained-release solid preparation for oral use
US20250025466A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2023539847A (ja) 肺線維症を治療するためのフェンレチニド又はその類似体の使用
JP6088429B2 (ja) 関節リウマチなどの自己免疫疾患の治療の改善方法
WO2017093444A1 (en) Compositions for oral administration in the treatment of inflammatory bowel disease
WO2019009359A1 (ja) 経鼻投与用医薬組成物
KR102465736B1 (ko) 정제 및 이의 제조방법
JP4045301B2 (ja) 肺胞破壊によって生じる肺疾患の治療または予防のためのクラリスロマイシンまたはその塩
JP2021522177A (ja) イオン輸送体の活性を増強するための組成物および方法ならびにその使用
AU2021242812A1 (en) Use of fenretinide for the treatment of SARS-corona virus infection
HK40047399A (en) Cenicriviroc combination therapy for the treatment of fibrosis
RS61955B1 (sr) Farmaceutska kompozicija koja sadrži darunavir i postupak za njegovo dobijanje
BR112018070626B1 (pt) Formulação farmacêutica e uso da mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202